Effect of deutetrabenazine on chorea among patients with huntington disease : A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 316, Issue 1, 2016, Pages 40-50

  Frank, Samuel ^a   Testa, Claudia M ^b   Stamler, David ^c   Kayson, Elise ^d   Davis, Charles ^e   Edmondson, Mary C ^f   Kinel, Shari ^g   Leavitt, Blair ^h   Oakes, David ⁱ   O'Neill, Christine ^j   Vaughan, Christina ^k   Goldstein, Jody ^d   Herzog, Margaret ^d   Snively, Victoria ^d   Whaley, Jacquelyn ^d   Wong, Cynthia ^c   Suter, Greg ^l   Jankovic, Joseph ^m   Jimenez Shahed, Joohi ^m   Hunter, Christine ^m   Claassen, Daniel O ⁿ   Roman, Olivia C ⁿ   Sung, Victor ^o   Smith, Jenna ^o   Janicki, Sarah ^p   Clouse, Ronda ^p   Saint Hilaire, Marie ^q   Hohler, Anna ^q   Turpin, Denyse ^q   James, Raymond C ^q   Rodriguez, Ramon ^r   Rizer, Kyle ^r   Anderson, Karen E ^s   Heller, Hope ^s   Carlson, Alexis ^p   Criswell, Susan ^t   Racett, Brad A ^t   Revilla, Fredy J ^u,v   Nucifora, Frederick ^w   Margolis, Russell L ^w   Ong, Mary Jane ^w   Mendis, Tilak ^x   Mendis, Neila ^x   Singer, Carlos ^y   Quesada, Monica ^y   Paulsen, Jane S ^z   Brashers Krug, Thomas ^z   Miller, Amanda ^z   Kerr, Jane ^z   Dubinsky, Richard M ^aa   Gray, Carolyn ^aa   Factor, Stewart A ^ab   Sperin, Elaine ^ab   Molho, Eric ^ac   Eglow, Mary ^ac   Evans, Sharon ^ac   Kumar, Rajeev ^ad   Reeves, Christina ^ad   Samii, Ali ^ae   Chouinard, Sylvain ^af   Beland, Monica ^ag   Scott, Burton L ^f   Hickey, Patrick T ^f   Esmail, Sherali ^ah   Fung, Wai Lun Alan ^ah,ai,aj   Gibbons, Clare ^ah,ai   Qi, Lina ^ah   Colcher, Amy ^ak   Hackmyer, Cory ^ak   McGarry, Andrew ^ak   Klos, Kevin ^al   Gudesblatt, Mark ^am   Fafard, Lori ^am   Graffitti, Laura ^am   Schneider, Daniel P ^an   Dhall, Rohit ^ao   Wojcieszek, Joanne M ^ap   La Faver, Kathrin ^aq   Duker, Andrew ^ar   Neefus, Erin ^ar   Wilson Perez, Hilary ^ar   Shprecher, David ^as,at   Wall, Paola ^au   Blindauer, Karen A ^au   Wheeler, Lynn ^au   Boyd, James T ^av   Houston, Emily ^av   Farbman, Eric S ^aw   Agarwal, Pinky ^ax   Eberly, Shirley W ⁱ   Watts, Arthur ⁱ   Tariot, Pierre N ^ay   Feigin, Andrew ^az   Evans, Scott ^ba   Beck, Chris ⁱ   Orme, Constance ⁱ   Edicola, Jon ⁱ   Christopher, Emily ^ba   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Teva Pharmaceutical Ltd   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e CSD Biostatistics ^*  (United States)

^f DUKE UNIVERSITY   (United States)

^g Huntington Study Group   (United States)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF ROCHESTER   (United States)

^j WAKE FOREST SCHOOL OF MEDICINE   (United States)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l Hereditary Neurological Disease Centre   (United States)

^m BAYLOR COLLEGE OF MEDICINE   (United States)

ⁿ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^o UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^p Och Spine at New York Presbyterian Hospitals   (United States)

^q BOSTON UNIVERSITY   (United States)

^r UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^s GEORGETOWN UNIVERSITY   (United States)

^t WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^u GREENVILLE HOSPITAL SYSTEM   (United States)

^v UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE GREENVILLE   (United States)

^w JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^x Parkinson's and Neurodegenerative Disorders Clinic   (Canada)

^y UNIVERSITY OF MIAMI   (United States)

^z UNIVERSITY OF IOWA   (United States)

^aa UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^ab EMORY UNIVERSITY   (United States)

^ac ALBANY MEDICAL COLLEGE   (United States)

^ad Rocky Mountain Movement Disorders Center   (United States)

^ae UNIVERSITY OF WASHINGTON   (United States)

^af CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^ag NOTRE DAME HOSPITAL   (Canada)

^ah NORTH YORK GENERAL HOSPITAL   (Canada)

^ai UNIVERSITY OF TORONTO   (Canada)

^aj UNIVERSITY HEALTH NETWORK   (Canada)

^ak Department of Anesthesiology   (United States)

^al Movement Disorders Clinic Oklahoma   (United States)

^am South Shore Neurologic Associates   (United States)

^an ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^ao PARKINSON S INSTITUTE   (United States)

^ap INDIANA UNIVERSITY   (United States)

^aq UNIVERSITY OF LOUISVILLE   (United States)

^ar UNIVERSITY OF CINCINNATI   (United States)

^as UNIVERSITY OF UTAH   (United States)

^at SUN HEALTH RESEARCH INSTITUTE   (United States)

^au MEDICAL COLLEGE OF WISCONSIN   (United States)

^av UNIVERSITY OF VERMONT   (United States)

^aw UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^ax Evergreen Neuroscience Institute   (United States)

^ay BANNER ALZHEIMER S INSTITUTE   (United States)

^az FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^ba HARVARD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEUTERIUM; DEUTETRABENAZINE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; CYTOCHROME P450 2D6; TETRABENAZINE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CHOREA; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE ACTIVITY SCORE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HUNTINGTON CHOREA; INSOMNIA; MALE; MOTOR DYSFUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; XEROSTOMIA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; HUNTINGTON DISEASE; MAINTENANCE CHEMOTHERAPY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; TREATMENT OUTCOME;

ADRENERGIC UPTAKE INHIBITORS; CHOREA; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HUNTINGTON DISEASE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; TETRABENAZINE; TREATMENT OUTCOME;

EID: 84977592334     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.8655     Document Type: Article

References (30)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72 (6):971-983.
2. Young AB, Shoulson I, Penney JB, et al. Huntington's disease in Venezuela: Neurologic features and functional decline. Neurology. 1986;36 (2):244-249.
3. Jankovic J, Roos RA. Chorea associated with Huntington's disease: To treat or not to treat? Mov Disord. 2014;29(11):1414-1418.
4. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology. 2006;66 (3):366-372.
5. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11 (11):1509-1523.
6. Guengerich FP. Kinetic deuterium isotope effects in cytochrome P450 oxidation reactions. J Labelled Comp Radiopharm. 2013;56(9-10):428- 431.
7. Foster AB. Deuterium isotope effects in studies of drug metabolism. Trends Pharmacol Sci. 1984;5 (0):524-527.
8. Gant TG. Using deuterium in drug discovery: Leaving the label in the drug. J Med Chem. 2014;57 (9):3595-3611.
9. Stamler D, BradburyM, Brown F. The pharmacokinetics and safety of deuterated-tetrabenazine. Neurology. 2013;80(7 supplement):P07.210.
10. Huntington Study Group. Unified Huntington's Disease Rating Scale: Reliability and consistency. Mov Disord. 1996;11(2):136-142.
11. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6): 361-370.
12. Snaith RP. The Hospital Anxiety and Depression (HADS) scale. Qual Life Outomes. 2003;1:29.
13. Perez Lloret S, Piran Arce G, Rossi M, Caivano NemetML, Salsamendi P, Merello M. Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease. Mov Disord. 2007;22(1): 107-111.
14. Fahn S, Elton RL; Members of the UDC. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Development in Parkinson's Disease. Vol 2. Florham Park, NJ:Macmillan Healthcare Information; 1987:153- 163.
15. Kamper SJ, Maher CG, Mackay G. Global rating of change scales: A review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2009;17(3):163-170.
16. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27(1):26-35.
17. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change: The Alzheimer's Disease Cooperative study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S22-S32.
18. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36), I: Conceptual framework and item selection. Med Care. 1992;30 (6):473-483.
19. Berg K,Wood-Dauphine S, Williams J-I, Gayton D. Measuring balance in the elderly: Preliminary development of an instrument. Physiother Can. 1989;41(6):304-311.
20. Armstrong MF,Miyasaki JM. Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;9:597-603.
21. JohnsMW. A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep. 1991;14(6):540-545.
22. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.
23. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
24. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool formild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
25. Dorsey ER, Beck CA, Darwin K, et al; Huntington Study Group COHORT Investigators. Natural history of Huntington disease. JAMA Neurol. 2013;70(12):1520-1530.
26. Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington's and Other Diseases. Tremor Other HyperkinetMov (N Y). 2013;3:3.
27. Frank S, Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs. 2010;70(5):561-571.
28. Marder K, Gu Y, Eberly S, et al; Huntington Study Group PHAROS Investigators. Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol. 2013;70(11):1382-1388.
29. Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28(2):210-215.
30. Kushner DJ, Baker A, Dunstall TG. Pharmacological uses and perspectives of heavy water and deuterated compounds. Can J Physiol Pharmacol. 1999;77(2):79-88.